Online Inquiry

Radiolabelling and Radiosynthesis Services

At Rdcthera, we are committed to advancing radiopharmaceuticals by offering comprehensive CRO services. We provide a full range of solutions, including the design, synthesis, preparation, and release of radiolabelled compounds, supporting pharmaceutical companies, biotech firms, and research institutions in developing innovative diagnostic and therapeutic agents.

Radiolabelling and Radiosynthesis Overview

Radiolabelling and radiosynthesis belong to the most important processes while developing radiopharmaceuticals. These methods allow adding radioactive isotopes to certain chemical compounds that could find use in further development, diagnostic imaging, targeted radiotherapy, etc. Rdcthera uses much collective experience in chemistry, biology, and physics to provide accurate and reliable radiolabelling and radiosynthesis services.

Fig 1. Different methods for radiolabelling liposomes.Fig. 1. Schematic illustration of the different methods for radiolabelling liposomes. (Man F, et al., 2019)

Our Service Offerings

Rdcthera offers a comprehensive array of radiolabelling and radiosynthesis services, encompassing the choice of the position where the molecule is to be labelled, chemical pathway optimization for radiosynthesis, the synthesis of a radiopharmaceutical, the analysis, purification, and recovery of the radiolabeled compounds.

  • Radioisotope Synthesis Services

We provide synthesis services for standards and isotope-labelled internal standards, essential for quantitative analyses in various research and clinical applications. Our services include

  • Position selection of radioisotope labeling
  • Optimization of synthesis route
  • Purification and analysis of radioisotope
  • R&D services for isotope-labelled compounds
  • Pharmaceutical Research and Analysis Services of Radioisotope

We use radioisotopes 32P, 33P, 125I, 35S, 89Zr, etc. in the aspect of labeling experiments in the drug discovery process. Our research services encompass the whole phases of radiopharmaceutical development from initial research to preclinical research.

  • Pharmacokinetic and pharmacodynamic studies of radiolabeled compounds
  • Biodistribution and dosimetry studies
  • Stability testing and shelf life determination
  • Comprehensive analytical services including HPLC, LC-MS/MS, and gamma counting
  • Radiolabeled Compounds Synthesis Services

Rdcthera offers synthesis of aromatic compounds, heterocyclic compounds, polypeptides, oligonucleotides, conjugates, polymers, including chiral compounds, antibody-drug conjugates (ADCs), and linkers thereof

  • Customized synthesis of radiolabeled compounds for research and development
  • Radiolabeled probes for molecular imaging
  • Radiolabeled drug synthesis for therapeutic application

Our Isotope Capabilities

Rdcthera has worked with a variety of projects involving common SPECT/PET isotopes. We also support conjugation with fluorophores, as well as 'cold' radiolabeling with non-radioactive elements.

SPECT Isotopes
99mTc 123I 111In 201TI
177Lu 131I
PET Isotopes
13N 11C 68Ga 18F
64Cu 89Zr 124I 52Mn
Other Available Isotopes
213Bi 90Y 225Ac 32P
3H 14C

Our Technology and Platforms

Our advanced technological infrastructure supports a wide range of radiolabelling and radiosynthesis projects. We employ cutting-edge platforms and methodologies, such as infrared spectroscopy, mass spectrometry, liquid chromatography (radioactivity detection and polymer characterization), gas chromatography, NMR differential scanning calorimetry, thermogravimetric analysis and ICP-MS, bioburden test and XRPD analysis.

Applications of Radiolabelling and Radiosynthesis

The radiolabeled compounds and radiopharmaceuticals we develop have a wide array of applications, including

  • Diagnostic imaging; for example, PET and SPECT
  • Targeted radiotherapy for cancer treatment
  • Pre-clinical and clinical research studies
  • Drug development and pharmacological research

To find out more about how Rdcthera can support your radiopharmaceutical research and development, please contact us. Our team will collaborate with you so you reach your scientific and preclinical goals.


  1. Man F, Gawne PJ, T M de Rosales R. (2019). Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine. Adv Drug Deliv Rev. 143:134-160.
For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy